查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1806333

抗菌藥物市場：2025-2030 年全球預測，按藥物類別、給藥途徑、分子類型、活性頻譜、作用機制、劑型、適應症、銷售點和分銷管道分類

Antibacterial Drugs Market by Drug Class, Route Of Administration, Molecule Type, Spectrum Of Activity, Mechanism of Action, Formulation, Indication, Point of Sale, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

抗生素市場預計到 2024 年將達到 517.7 億美元，2025 年將達到 540.5 億美元，2030 年將達到 675.9 億美元，複合年成長率為 4.54%。

主要市場統計數據
基準年2024年 517.7億美元
預計2025年 540.5億美元
預測年份 2030 675.9億美元
複合年成長率（%） 4.54%

探索抗菌治療在應對現代感染疾病挑戰中的重要角色和進化動態

感染性病原體的出現和快速進化使抗菌治療成為全球醫療保健領域的首要任務。過去十年，人們對抗菌藥物抗藥性的擔憂日益加劇，這促使人們加強研究力度並加強監管審查，從而催生了一系列旨在克服多重抗藥性細菌頑強抵抗力的創新。在此背景下，本報告深入探討了圍繞抗生素的複雜動態，並檢驗了科學突破、政策轉變和以患者為中心的需求如何共同決定現有療法和新興療法的發展軌跡。

顛覆性的技術進步和監管模式轉移將塑造抗生素開發和部署的未來格局

抗生素領域正在經歷一場由技術、監管和臨床創新融合推動的重大變革時期。計算生物學和人工智慧的進步徹底改變了目標識別，使研究人員能夠以前所未有的速度預測抗藥性機制並最佳化先導化合物。同時，監管機構正在採用快速核准途徑和新的獎勵框架，以應對抗生素研發史上緩慢的步伐。這些監管轉變不僅將加速重要治療方法的可及性，還將鼓勵公共和私營部門實體之間的合作。

評估2025年美國關稅政策對全球供應鏈和抗生素取得的深遠影響

2025年美國新關稅的實施，正在對全球抗生素供應鏈產生連鎖反應，改變成本結構並影響採購決策。關鍵中間體的關稅上調導致原料成本上升，迫使製造商重新評估戰略夥伴關係並開發其他採購地點。因此，曾經具有成本效益的生產基地如今正努力在價格競爭力和合規性之間取得微妙的平衡。

全面分析治療層級、給藥途徑、分子類型以及其他推動抗生素市場細分的關鍵因素

從多個角度檢驗抗菌藥物市場細分，可以發現深刻的見解。依藥物類別，市場分為Aminoglycosides、BETA-內醯胺類、大環內酯類、奎諾酮、磺胺類藥物及四環黴素。Aminoglycosides，包括Amikacin、慶大霉素、鏈黴素和妥布黴素，佔據主導地位；BETA-內醯胺類藥物包括卡巴培南類、頭孢菌素類、單環胺基類和青黴素類。依給藥途徑進行平行細分，涵蓋口服、腸外和局部製劑的多種用途，每種製劑均針對不同的患者需求和護理環境量身定做。

對美洲、歐洲、中東和非洲以及亞太市場的市場促進因素、挑戰和成長前景進行策略性審查

流行病學、法律規範和醫療保健基礎設施的地區差異在塑造抗生素格局方面發揮關鍵作用。在美洲，持續的研發投入催生了一批強勁的新型化合物，但不斷上升的抗生素抗藥性和嚴峻的價格壓力使得持續的監管工作勢在必行。付款人模式強調基於價值的契約，鼓勵製造商同時證明臨床療效和成本效益。

剖析關鍵創新者和市場領導：頂級抗生素製造商的策略定位和競爭動態

抗菌療法的競爭格局由跨國製藥公司、專業生物技術公司和知名非專利製造商組成。領先的開發商正在利用廣泛的篩檢基礎設施和高通量篩選平台，將First-in-Class分子推進到後期開發階段。同時，敏捷的生物技術公司正在利用其在新型治療方法（例如噬菌體和肽類療法）方面的專業知識，建立專門的產品組合，以應對新興的抗藥性機制。

相關人員面臨的策略挑戰和戰術性建議，以增強創新、市場滲透和病患治療效果

為了維持抗生素藥物研發的領先地位，相關人員必須優先對核心競爭力進行有針對性的投資，同時促進跨部門合作。首先，透過整合診斷主導方案來加強抗生素管理項目，可以最佳化患者療效，並延長現有藥物的臨床效用。同時，擴大與學術機構和受託研究機構的研究夥伴關係，可以加速發現新的作用機制，並降低研發管線枯竭的風險。

我們嚴謹的調查方法整合了廣泛的一手和二手資料，為抗生素市場提供了全面可靠的見解。

本報告採用嚴謹的調查方法，確保研究結果的有效性和可靠性。報告首先進行了廣泛的一手資料研究，包括對關鍵意見領袖、臨床醫生和供應鏈高管的深入訪談。此外，我們也對包括同儕審查日誌、監管出版物和專有專利資料庫在內的二手資料進行了全面的審查，進一步完善了這些定性見解。

綜合關鍵見解和未來觀點，重點介紹不斷發展的抗菌治療領域中的關鍵機會和挑戰

綜合本文的廣泛分析，我們得出了幾個將定義抗生素創新下一階段的總體主題。克服抗生素抗藥性的迫切性要求持續投資於新型治療方法和協作管理框架。同時，不斷變化的監管格局和貿易政策凸顯了供應鏈敏捷性和跨境夥伴關係的重要性。能夠巧妙地協調研究工作、商業策略和以患者為中心的模式的相關人員將最有可能抓住新的機會。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章市場動態

  • 擴大採用人工智慧驅動的抗生素發現平台可加速新化合物的識別和最佳化
  • 基於 CRISPR 的抗菌療法的發展使得能夠針對性地消除多重抗藥性菌株的基因
  • 擴大吸入抗生素治療囊腫纖維化患者的抗藥性肺部感染疾病
  • 開發旨在透過誘導靶向免疫反應來預防細菌感染的 mRNA 疫苗平台
  • 加大對旨在廣譜破壞細菌膜的合成抗菌肽研究的投入
  • 整合分散式定序技術，實現醫院病原體即時監測與個人化治療決策
  • 非抗生素藥物作為輔助性治療的使用激增，以加速細菌消除並減少抗藥性的產生。
  • 有條件批准耐卡巴培南類腸桿菌科細菌感染疾病抗生素聯合治療的監管進展
  • 人們開始轉向使用保留微生物群的窄效抗生素，以便在治療期間保護有益的常駐菌叢。
  • 加速公私合作資助舉措，支持全球針對關鍵優先病原體的抗生素研發

第6章 市場洞察

  • 波特五力分析
  • PESTEL分析

第7章 2025年美國關稅的累積影響

第 8 章：抗生素市場（依藥物類別）

  • Aminoglycosides
    • Amikacin
    • 慶大霉素
    • 鏈黴素
    • 妥布黴素
  • BETA-內醯胺類
    • 卡巴培南類
    • 頭孢菌素類
    • 單環胺基類
    • 青黴素
  • 大環內酯類
  • 奎諾酮
  • 磺胺類藥物
  • 四環黴素

第9章抗生素市場（依給藥途徑）

  • 口服
  • 腸外
  • 話題

第 10 章：按分子類型分類的抗菌藥物市場

  • 品牌
  • 非專利的

第 11 章：抗生素市場活動頻譜

  • 頻譜
  • 窄頻頻譜

第 12 章：抗生素市場（依作用機制）

  • 細胞壁抑制劑
  • DNA抑制劑
  • 蛋白質合成抑制劑

第 13 章：處方抗生素市場

  • 膠囊
  • 液體
  • 粉末
  • 藥片

第 14 章：抗生素市場（按適應症）

  • 呼吸道感染疾病
  • 性行為感染傳染病
  • 皮膚感染疾病
  • 尿道感染

第 15 章抗生素市場銷售點

  • 非處方藥
  • 處方藥

第 16 章：抗生素市場（依通路）

  • 離線
    • 醫院藥房
    • 零售藥局
  • 線上

17. 美國抗生素市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

第 18 章：歐洲、中東和非洲的抗生素市場

  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 阿拉伯聯合大公國
  • 沙烏地阿拉伯
  • 南非
  • 丹麥
  • 荷蘭
  • 卡達
  • 芬蘭
  • 瑞典
  • 奈及利亞
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波蘭
  • 瑞士

19. 亞太地區抗生素市場

  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • 印尼
  • 泰國
  • 菲律賓
  • 馬來西亞
  • 新加坡
  • 越南
  • 台灣

第20章 競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Pfizer Inc.
    • Merck & Co., Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Taj Pharmaceuticals Limited
    • Sun Pharmaceutical Industries Limited
    • Shionogi & Co., Ltd.
    • Saphnix Life Sciences
    • Sanofi SA
    • Novartis AG
    • Nabriva Therapeutics PLC by Sumitomo Pharma Co., Ltd.
    • Melinta Therapeutics LLC
    • Lupin Limited
    • Kyorin Pharmaceutical Co., Ltd.
    • Johnson & Johnson Services, Inc.
    • Iterum Therapeutics PLC
    • Hikma Pharmaceuticals PLC
    • Glenmark Pharmaceuticals Limited
    • GlaxoSmithKline PLC
    • F. Hoffmann-La Roche AG
    • Entasis Therapeutics by Innoviva, Inc.
    • Eli Lilly and Company
    • Dr. Reddy's Laboratories Ltd.
    • Debiopharm Group
    • Cipla Limited
    • Century Pharmaceuticals Ltd.
    • Bristol-Myers Squibb Company
    • Bayer AG
    • Bausch Health Companies Inc.
    • AstraZeneca PLC
    • Astellas Pharma Inc.
    • Allecra Therapeutics GmbH
    • AbbVie Inc.
    • Abbott Laboratories

第21章 研究人工智慧

第22章 研究統計

第23章 研究聯絡人

第24章 研究報導

第25章 附錄

Product Code: MRR-4358BACA8012

The Antibacterial Drugs Market was valued at USD 51.77 billion in 2024 and is projected to grow to USD 54.05 billion in 2025, with a CAGR of 4.54%, reaching USD 67.59 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 51.77 billion
Estimated Year [2025] USD 54.05 billion
Forecast Year [2030] USD 67.59 billion
CAGR (%) 4.54%

Exploring the Critical Role and Evolutionary Dynamics of Antibacterial Therapies in Confronting Modern Infectious Disease Challenges

The emergence and rapid evolution of infectious pathogens have positioned antibacterial therapies at the forefront of global healthcare priorities. Over the past decade, escalating concerns regarding antimicrobial resistance have galvanized research efforts and regulatory scrutiny, spurring a new wave of innovation aimed at overcoming the resilience of multidrug-resistant organisms. Against this backdrop, this report delves into the multifaceted dynamics of the antibacterial drugs landscape, examining how scientific breakthroughs, policy shifts, and patient-centric demands converge to dictate the trajectory of both established and emerging therapies.

Incorporating both historical context and contemporary developments, the analysis traces the shifting paradigm from broad-spectrum agents to precision-targeted molecules, underscoring the critical interplay between efficacy, safety, and stewardship. Moreover, the introduction of novel modalities-including bacteriophage therapies and antimicrobial peptides-signals a renaissance in drug discovery that is reshaping traditional R&D pathways. By articulating the strategic imperatives for manufacturers, payers, and healthcare providers alike, this section establishes the foundational themes that resonate throughout the ensuing report.

Disruptive Technological Advancements and Regulatory Paradigm Shifts Shaping the Future Landscape of Antibacterial Therapy Development and Deployment

The antibacterial drugs sector is undergoing a profound transformation driven by converging technological, regulatory, and clinical innovations. Advances in computational biology and artificial intelligence are revolutionizing target identification, enabling researchers to predict resistance mechanisms and optimize lead compounds with unprecedented speed. Concurrently, regulatory bodies have begun to adopt accelerated approval pathways and novel incentive frameworks to counteract the historically slow pace of antibacterial drug development. This regulatory shift not only expedites access to critical therapies but also encourages collaboration between public agencies and private enterprises.

Furthermore, the integration of real-world evidence and digital health tools is enhancing post-launch surveillance and patient adherence, thereby reinforcing antimicrobial stewardship while ensuring optimal therapeutic outcomes. These pioneering approaches, coupled with cross-sector alliances that span academia, biotech, and established pharmaceutical giants, are redefining the contours of market entry and competitive strategy. As a result, industry stakeholders must continuously adapt to these dynamic forces to capitalize on emerging opportunities and mitigate the persistent challenges posed by resistant pathogens.

Assessing the Far-Reaching Consequences of 2025 United States Tariff Policies on Global Supply Chains and Access to Antibacterial Medications

The introduction of new tariff measures by the United States in 2025 has generated ripple effects throughout the global antibacterial supply chain, altering cost structures and influencing sourcing decisions. Higher duties on key intermediates have augmented raw material expenses, compelling manufacturers to reassess strategic partnerships and explore alternative procurement hubs. Consequently, regions that previously served as cost-effective production centers are now navigating a delicate balance between price competitiveness and regulatory compliance.

Moreover, the tariff landscape has intensified the need for supply chain diversification, prompting stakeholders to establish secondary manufacturing facilities and leverage regional free trade agreements. This strategic realignment not only safeguards against geopolitical volatility but also preserves continuity of supply for critical therapies. Simultaneously, heightened import costs have exerted upward pressure on list prices, necessitating enhanced negotiations with payers and healthcare systems. Ultimately, understanding the cumulative impact of these policies is essential for developing robust mitigation strategies that ensure both affordability and accessibility of antibacterial treatments worldwide.

Comprehensive Analysis of Therapeutic Classes, Administration Routes, Molecule Types and Other Key Factors Driving Segmentation in Antibacterial Markets

Market segmentation within the antibacterial drugs domain reveals nuanced insights when examined through multiple lenses. The classification by drug class spans aminoglycosides, beta-lactams, macrolides, quinolones, sulfonamides, and tetracyclines; within aminoglycosides, agents such as amikacin, gentamicin, streptomycin, and tobramycin warrant particular attention, while beta-lactams encompass carbapenems, cephalosporins, monobactams, and penicillins. Parallel differentiation by route of administration captures the diverse applications of oral, parenteral, and topical formulations, each aligning to distinct patient needs and care settings.

When evaluating molecule type, the juxtaposition of branded versus generic options underscores the ongoing tension between innovation incentives and cost containment. In terms of spectrum of activity, the choice between broad spectrum and narrow spectrum compounds drives prescribing behaviors and stewardship priorities. Mechanism of action further stratifies the market into cell wall inhibitors, DNA inhibitors, and protein synthesis inhibitors, each governing distinct therapeutic niches. The formulation dimension-ranging from capsules to liquids, powders, and tablets-reflects considerations around patient compliance and dosage precision. Indication-based segmentation highlights the burden of respiratory, sexually transmitted, skin, and urinary tract infections, delineating where unmet needs persist. Finally, the point of sale distinction between over-the-counter and prescription models, alongside the distribution channel analysis of offline outlets such as hospital and retail pharmacies versus online platforms, illuminates the evolving pathways through which antibacterial agents reach end users.

Strategic Examination of Regional Drivers, Challenges, and Growth Prospects Across the Americas, Europe, Middle East & Africa, and Asia-Pacific Markets

Geographic variations play a pivotal role in shaping the antibacterial drugs landscape, as regional epidemiology, regulatory frameworks, and healthcare infrastructures diverge significantly. In the Americas, sustained investment in research and development has yielded a robust pipeline of novel compounds, yet rising antimicrobial resistance rates and stringent pricing pressures necessitate ongoing stewardship initiatives. Payer models emphasize value-based contracting, encouraging manufacturers to demonstrate both clinical efficacy and cost-effectiveness.

Shifting to the Europe, Middle East & Africa region, a mosaic of regulatory regimes and healthcare delivery systems presents both opportunities and challenges. Western European markets benefit from well-established reimbursement mechanisms and collaborative antimicrobial resistance surveillance programs, whereas emerging economies within Africa and the Middle East grapple with access constraints and infrastructural gaps. Nevertheless, increasing public-private partnerships are beginning to address diagnostic bottlenecks and distribution inefficiencies.

Meanwhile, the Asia-Pacific arena is characterized by rapid market expansion driven by growing patient populations, rising incomes, and enhanced local manufacturing capabilities. Policymakers across the region are implementing stringent controls on antibiotic usage, while regional biotech clusters are accelerating indigenous innovation. As a result, stakeholders must adopt region-specific strategies that reconcile local regulatory requirements with global development objectives.

Profiling Leading Innovators and Market Leaders: Strategic Positioning and Competitive Dynamics Among Top Antibacterial Drug Manufacturers

The competitive landscape of antibacterial therapeutics features a blend of multinational pharmaceutical corporations, specialized biotechnology firms, and prominent generic manufacturers. Leading innovators continue to leverage extensive R&D infrastructures and high-throughput screening platforms to advance first-in-class molecules through late-stage development. Concurrently, agile biotech enterprises harness niche expertise in emerging modalities, such as bacteriophage and peptide-based therapies, carving out specialized portfolios that address pressing resistance mechanisms.

Generic players, supported by streamlined manufacturing processes and established distribution channels, remain integral to maintaining affordability and accessibility. Their capacity to swiftly introduce cost-effective alternatives upon patent expiry exerts downward pressure on overall treatment costs, fostering broader adoption in price-sensitive markets. The interplay between these cohorts drives dynamic partnerships, licensing agreements, and merger-acquisition activities, shaping an ecosystem where strategic collaboration and competitive differentiation coexist. Both large and small organizations must therefore navigate a terrain defined by technological convergence, evolving regulatory incentives, and shifting payer expectations.

Strategic Imperatives and Tactical Recommendations for Industry Stakeholders to Enhance Innovation, Market Penetration, and Patient Outcomes

To remain at the vanguard of antibacterial drug development, industry stakeholders must prioritize targeted investments in core capabilities while fostering cross-sector collaboration. Firstly, strengthening antimicrobial stewardship programs through integrated diagnostic-driven protocols will optimize patient outcomes and prolong the clinical utility of existing agents. Simultaneously, expanding research partnerships with academic institutions and contract research organizations can accelerate the discovery of novel mechanisms of action, mitigating pipeline attrition risks.

Operationally, diversifying supply chain networks by establishing dual-sourcing strategies and regional manufacturing hubs can enhance resilience against geopolitical disruptions and tariff impositions. Embracing digital-enabled clinical trials and real-world evidence platforms will streamline development timelines and inform adaptive trial designs. Furthermore, proactive engagement with regulatory authorities to shape incentive frameworks and clarifying approval pathways will expedite market entry for breakthrough therapies. Finally, aligning commercial models to value-based contracting and patient support initiatives can reinforce market access, driving sustainable growth and improved public health outcomes.

Robust Research Methodology Integrating Diverse Primary and Secondary Data Sources Ensuring Comprehensive and Reliable Antibacterial Market Insights

This report employs a rigorous research methodology designed to ensure the validity and reliability of its findings. Initially, the analysis integrated extensive primary research, including in-depth interviews with key opinion leaders, clinical practitioners, and supply chain executives. These qualitative insights were complemented by a thorough review of secondary sources, encompassing peer-reviewed journals, regulatory agency publications, and proprietary patent databases.

Quantitative validation was achieved through cross-referencing multiple data repositories and triangulating supply chain metrics with prescription volume statistics. Throughout the process, proprietary analytical frameworks were applied to assess market drivers, technology adoption curves, and competitive positioning. Data integrity was maintained via iterative fact-checking and peer review by domain experts, ensuring that conclusions reflect the most current industry developments. This methodological approach underpins the strategic recommendations and reinforces the credibility of the market insights presented.

Synthesis of Critical Findings and Future Perspectives Highlighting Key Opportunities and Challenges in the Evolving Antibacterial Therapeutics Landscape

Drawing together the extensive analyses contained herein, several overarching themes emerge that will define the next phase of antibacterial drug innovation. The imperative to overcome antimicrobial resistance necessitates continued investment in novel modalities and collaborative stewardship frameworks. At the same time, evolving regulatory landscapes and trade policies underscore the importance of supply chain agility and cross-border partnerships. Stakeholders who adeptly align research endeavors, commercial strategies, and patient-centric models will be best positioned to capture emerging opportunities.

As the industry contends with the delicate balance between innovation incentives and affordability pressures, the ability to adapt to regional nuances will prove crucial. Future success will hinge on integrated approaches that harness technological breakthroughs, data-driven insights, and strategic alliances. Ultimately, the resilience of the antibacterial drugs market will depend on sustained commitment across public and private sectors to deliver effective, accessible therapies that address the global burden of infectious disease.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Rising adoption of AI-driven antibiotic discovery platforms to accelerate novel compound identification and optimization
  • 5.2. Growth of CRISPR-based antibacterial therapies offering gene-targeted elimination of multidrug-resistant bacterial strains
  • 5.3. Expansion of inhalable antibiotic formulations targeting resistant pulmonary infections in cystic fibrosis populations
  • 5.4. Development of mRNA vaccine platforms designed to prevent bacterial infections by inducing targeted immune responses
  • 5.5. Rising investments in synthetic antimicrobial peptide research for broad-spectrum bacterial membrane disruption
  • 5.6. Integration of decentralized sequencing technologies for real-time hospital pathogen surveillance and tailored therapy decisions
  • 5.7. Surge in repurposing non-antibiotic drugs as adjunctive therapies to enhance bacterial clearance and reduce resistance emergence
  • 5.8. Regulatory momentum for conditional approvals of antibiotic combination therapies addressing carbapenem-resistant Enterobacteriaceae infections
  • 5.9. Growing shift toward microbiome-sparing narrow-spectrum antibiotics to preserve beneficial commensal flora during treatment courses
  • 5.10. Accelerated public-private funding initiatives supporting global antibiotic pipeline against critical priority pathogens

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Antibacterial Drugs Market, by Drug Class

  • 8.1. Introduction
  • 8.2. Aminoglycosides
    • 8.2.1. Amikacin
    • 8.2.2. Gentamicin
    • 8.2.3. Streptomycin
    • 8.2.4. Tobramycin
  • 8.3. Beta-Lactams
    • 8.3.1. Carbapenems
    • 8.3.2. Cephalosporins
    • 8.3.3. Monobactams
    • 8.3.4. Penicillins
  • 8.4. Macrolides
  • 8.5. Quinolones
  • 8.6. Sulfonamides
  • 8.7. Tetracyclines

9. Antibacterial Drugs Market, by Route Of Administration

  • 9.1. Introduction
  • 9.2. Oral
  • 9.3. Parenteral
  • 9.4. Topical

10. Antibacterial Drugs Market, by Molecule Type

  • 10.1. Introduction
  • 10.2. Branded
  • 10.3. Generic

11. Antibacterial Drugs Market, by Spectrum Of Activity

  • 11.1. Introduction
  • 11.2. Broad Spectrum
  • 11.3. Narrow Spectrum

12. Antibacterial Drugs Market, by Mechanism of Action

  • 12.1. Introduction
  • 12.2. Cell Wall Inhibitors
  • 12.3. DNA Inhibitors
  • 12.4. Protein Synthesis Inhibitors

13. Antibacterial Drugs Market, by Formulation

  • 13.1. Introduction
  • 13.2. Capsules
  • 13.3. Liquid
  • 13.4. Powder
  • 13.5. Tablets

14. Antibacterial Drugs Market, by Indication

  • 14.1. Introduction
  • 14.2. Respiratory Infections
  • 14.3. Sexually Transmitted Infections
  • 14.4. Skin Infections
  • 14.5. Urinary Tract Infections

15. Antibacterial Drugs Market, by Point of Sale

  • 15.1. Introduction
  • 15.2. Over-The-Counter Drugs
  • 15.3. Prescription Drugs

16. Antibacterial Drugs Market, by Distribution Channel

  • 16.1. Introduction
  • 16.2. Offline
    • 16.2.1. Hospital Pharmacy
    • 16.2.2. Retail Pharmacy
  • 16.3. Online

17. Americas Antibacterial Drugs Market

  • 17.1. Introduction
  • 17.2. United States
  • 17.3. Canada
  • 17.4. Mexico
  • 17.5. Brazil
  • 17.6. Argentina

18. Europe, Middle East & Africa Antibacterial Drugs Market

  • 18.1. Introduction
  • 18.2. United Kingdom
  • 18.3. Germany
  • 18.4. France
  • 18.5. Russia
  • 18.6. Italy
  • 18.7. Spain
  • 18.8. United Arab Emirates
  • 18.9. Saudi Arabia
  • 18.10. South Africa
  • 18.11. Denmark
  • 18.12. Netherlands
  • 18.13. Qatar
  • 18.14. Finland
  • 18.15. Sweden
  • 18.16. Nigeria
  • 18.17. Egypt
  • 18.18. Turkey
  • 18.19. Israel
  • 18.20. Norway
  • 18.21. Poland
  • 18.22. Switzerland

19. Asia-Pacific Antibacterial Drugs Market

  • 19.1. Introduction
  • 19.2. China
  • 19.3. India
  • 19.4. Japan
  • 19.5. Australia
  • 19.6. South Korea
  • 19.7. Indonesia
  • 19.8. Thailand
  • 19.9. Philippines
  • 19.10. Malaysia
  • 19.11. Singapore
  • 19.12. Vietnam
  • 19.13. Taiwan

20. Competitive Landscape

  • 20.1. Market Share Analysis, 2024
  • 20.2. FPNV Positioning Matrix, 2024
  • 20.3. Competitive Analysis
    • 20.3.1. Pfizer Inc.
    • 20.3.2. Merck & Co., Inc.
    • 20.3.3. Teva Pharmaceutical Industries Ltd.
    • 20.3.4. Taj Pharmaceuticals Limited
    • 20.3.5. Sun Pharmaceutical Industries Limited
    • 20.3.6. Shionogi & Co., Ltd.
    • 20.3.7. Saphnix Life Sciences
    • 20.3.8. Sanofi S.A.
    • 20.3.9. Novartis AG
    • 20.3.10. Nabriva Therapeutics PLC by Sumitomo Pharma Co., Ltd.
    • 20.3.11. Melinta Therapeutics LLC
    • 20.3.12. Lupin Limited
    • 20.3.13. Kyorin Pharmaceutical Co., Ltd.
    • 20.3.14. Johnson & Johnson Services, Inc.
    • 20.3.15. Iterum Therapeutics PLC
    • 20.3.16. Hikma Pharmaceuticals PLC
    • 20.3.17. Glenmark Pharmaceuticals Limited
    • 20.3.18. GlaxoSmithKline PLC
    • 20.3.19. F. Hoffmann-La Roche AG
    • 20.3.20. Entasis Therapeutics by Innoviva, Inc.
    • 20.3.21. Eli Lilly and Company
    • 20.3.22. Dr. Reddy's Laboratories Ltd.
    • 20.3.23. Debiopharm Group
    • 20.3.24. Cipla Limited
    • 20.3.25. Century Pharmaceuticals Ltd.
    • 20.3.26. Bristol-Myers Squibb Company
    • 20.3.27. Bayer AG
    • 20.3.28. Bausch Health Companies Inc.
    • 20.3.29. AstraZeneca PLC
    • 20.3.30. Astellas Pharma Inc.
    • 20.3.31. Allecra Therapeutics GmbH
    • 20.3.32. AbbVie Inc.
    • 20.3.33. Abbott Laboratories

21. ResearchAI

22. ResearchStatistics

23. ResearchContacts

24. ResearchArticles

25. Appendix

LIST OF FIGURES

  • FIGURE 1. ANTIBACTERIAL DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
  • FIGURE 16. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
  • FIGURE 18. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2024 VS 2030 (%)
  • FIGURE 20. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
  • FIGURE 22. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 24. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 25. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 26. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 27. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 28. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 29. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 30. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 31. ANTIBACTERIAL DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. ANTIBACTERIAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 33. ANTIBACTERIAL DRUGS MARKET: RESEARCHAI
  • FIGURE 34. ANTIBACTERIAL DRUGS MARKET: RESEARCHSTATISTICS
  • FIGURE 35. ANTIBACTERIAL DRUGS MARKET: RESEARCHCONTACTS
  • FIGURE 36. ANTIBACTERIAL DRUGS MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. ANTIBACTERIAL DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY AMIKACIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY AMIKACIN, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY GENTAMICIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY GENTAMICIN, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY STREPTOMYCIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY STREPTOMYCIN, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY TOBRAMYCIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY TOBRAMYCIN, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY CARBAPENEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY CARBAPENEMS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY CEPHALOSPORINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY CEPHALOSPORINS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY MONOBACTAMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY MONOBACTAMS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY PENICILLINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY PENICILLINS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY MACROLIDES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY QUINOLONES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY QUINOLONES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY SULFONAMIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY SULFONAMIDES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY TETRACYCLINES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY BROAD SPECTRUM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY BROAD SPECTRUM, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY NARROW SPECTRUM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY NARROW SPECTRUM, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY CELL WALL INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY CELL WALL INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DNA INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DNA INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY PROTEIN SYNTHESIS INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY PROTEIN SYNTHESIS INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY LIQUID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY LIQUID, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 77. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY POWDER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY POWDER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 79. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 81. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 83. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 85. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 87. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY SKIN INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY SKIN INFECTIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 89. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY URINARY TRACT INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY URINARY TRACT INFECTIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 91. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2025-2030 (USD MILLION)
  • TABLE 93. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 95. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 97. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 99. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 101. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 103. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 105. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 107. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 109. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 110. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 111. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2024 (USD MILLION)
  • TABLE 112. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2025-2030 (USD MILLION)
  • TABLE 113. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2024 (USD MILLION)
  • TABLE 114. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2025-2030 (USD MILLION)
  • TABLE 115. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 116. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 117. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 118. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
  • TABLE 119. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2024 (USD MILLION)
  • TABLE 120. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2025-2030 (USD MILLION)
  • TABLE 121. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 122. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
  • TABLE 123. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 124. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
  • TABLE 125. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 126. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 127. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2024 (USD MILLION)
  • TABLE 128. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2025-2030 (USD MILLION)
  • TABLE 129. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 130. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 131. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 132. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 133. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 135. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 136. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 137. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2024 (USD MILLION)
  • TABLE 138. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2025-2030 (USD MILLION)
  • TABLE 139. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2024 (USD MILLION)
  • TABLE 140. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2025-2030 (USD MILLION)
  • TABLE 141. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 142. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 143. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 144. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
  • TABLE 145. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2024 (USD MILLION)
  • TABLE 146. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2025-2030 (USD MILLION)
  • TABLE 147. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 148. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
  • TABLE 149. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 150. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
  • TABLE 151. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 152. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 153. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2024 (USD MILLION)
  • TABLE 154. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2025-2030 (USD MILLION)
  • TABLE 155. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 156. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 157. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 158. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 159. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 160. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 161. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 162. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 163. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2024 (USD MILLION)
  • TABLE 164. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2025-2030 (USD MILLION)
  • TABLE 165. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2024 (USD MILLION)
  • TABLE 166. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2025-2030 (USD MILLION)
  • TABLE 167. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 168. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 169. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 170. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
  • TABLE 171. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2024 (USD MILLION)
  • TABLE 172. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2025-2030 (USD MILLION)
  • TABLE 173. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 174. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
  • TABLE 175. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 176. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
  • TABLE 177. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 178. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 179. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2024 (USD MILLION)
  • TABLE 180. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2025-2030 (USD MILLION)
  • TABLE 181. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 182. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 183. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 184. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 185. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 186. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 187. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2024 (USD MILLION)
  • TABLE 188. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2025-2030 (USD MILLION)
  • TABLE 189. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2024 (USD MILLION)
  • TABLE 190. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2025-2030 (USD MILLION)
  • TABLE 191. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 192. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 193. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
  • TABLE 195. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2024 (USD MILLION)
  • TABLE 196. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2025-2030 (USD MILLION)
  • TABLE 197. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 198. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
  • TABLE 199. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 200. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
  • TABLE 201. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 202. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 203. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2024 (USD MILLION)
  • TABLE 204. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2025-2030 (USD MILLION)
  • TABLE 205. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 206. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 207. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 208. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 209. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 210. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 211. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2024 (USD MILLION)
  • TABLE 212. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2025-2030 (USD MILLION)
  • TABLE 213. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2024 (USD MILLION)
  • TABLE 214. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2025-2030 (USD MILLION)
  • TABLE 215. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 216. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 217. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
  • TABLE 219. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2024 (USD MILLION)
  • TABLE 220. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2025-2030 (USD MILLION)
  • TABLE 221. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 222. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
  • TABLE 223. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 224. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
  • TABLE 225. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 226. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 227. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2024 (USD MILLION)
  • TABLE 228. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2025-2030 (USD MILLION)
  • TABLE 229. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 230. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 231. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 232. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 233. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 234. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 235. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2024 (USD MILLION)
  • TABLE 236. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2025-2030 (USD MILLION)
  • TABLE 237. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2024 (USD MILLION)
  • TABLE 238. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2025-2030 (USD MILLION)
  • TABLE 239. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 240. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 241. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
  • TABLE 243. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2024 (USD MILLION)
  • TABLE 244. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2025-2030 (USD MILLION)
  • TABLE 245. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 246. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
  • TABLE 247. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 248. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
  • TABLE 249. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 250. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 251. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2024 (USD MILLION)
  • TABLE 252. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2025-2030 (USD MILLION)
  • TABLE 253. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 254. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 255. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 256. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2025-2030 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2025-2030 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2025-2030 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2025-2030 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 283. UNITED KINGDOM ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 284. UNITED KINGDOM ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 285. UNITED KINGDOM ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2024 (USD MILLION)
  • TABLE 286. UNITED KINGDOM ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2025-2030 (USD MILLION)
  • TABLE 287. UNITED KINGDOM ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2024 (USD MILLION)
  • TABLE 288. UNITED KINGDOM ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2025-2030 (USD MILLION)
  • TABLE 289. UNITED KINGDOM ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 290. UNITED KINGDOM ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 291. UNITED KINGDOM ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. UNITED KINGDOM ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
  • TABLE 293. UNITED KINGDOM ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2024 (USD MILLION)
  • TABLE 294. UNITED KINGDOM ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2025-2030 (USD MILLION)
  • TABLE 295. UNITED KINGDOM ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 296. UNITED KINGDOM ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
  • TABLE 297. UNITED KINGDOM ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 298. UNITED KINGDOM ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
  • TABLE 299. UNITED KINGDOM ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 300. UNITED KINGDOM ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 301. UNITED KINGDOM ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2024 (USD MILLION)
  • TABLE 302. UNITED KINGDOM ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2025-2030 (USD MILLION)
  • TABLE 303. UNITED KINGDOM ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 304. UNITED KINGDOM ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 305. UNITED KINGDOM ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 306. UNITED KINGDOM ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 307. GERMANY ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 308. GERMANY ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 309. GERMANY ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2024 (USD MILLION)
  • TABLE 310. GERMANY ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2025-2030 (USD MILLION)
  • TABLE 311. GERMANY ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2024 (USD MILLION)
  • TABLE 312. GERMANY ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2025-2030 (USD MILLION)
  • TABLE 313. GERMANY ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 314. GERMANY ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 315. GERMANY ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 316. GERMANY ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
  • TABLE 317. GERMANY ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2024 (USD MILLION)
  • TABLE 318. GERMANY ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2025-2030 (USD MILLION)
  • TABLE 319. GERMANY ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 320. GERMANY ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
  • TABLE 321. GERMANY ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 322. GERMANY ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
  • TABLE 323. GERMANY ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 324. GERMANY ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 325. GERMANY ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2024 (USD MILLION)
  • TABLE 326. GERMANY ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2025-2030 (USD MILLION)
  • TABLE 327. GERMANY ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 328. GERMANY ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 329. GERMANY ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 330. GERMANY ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 331. FRANCE ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)

TA